Skip to content

All Lessons

Q&A with Session Seven Speakers (REdI 2024 – Biologics Track)

Q&A with Session Six Speakers (REdI 2024 – Biologics Track)

Q&A with Session Three Speakers (REdI 2024 – Biologics Track)

Q&A with Session Two Speakers (REdI 2024 – Biologics Track)

Question & Answer Session (IDMP)

Question & Answer Session (Navigating Controlled Correspondences)

Question & Answer Session (OMUFA: Understanding FY 2025 User Fees)

Question & Answer Session (REMS)

Question & Answer Session and Closing Remarks (BsUFA III Science Pilot Program: Progress Update)

Question & Answer Session (M13A)

Reagan-Udall Foundation  

Recognized Consensus Standards: The Ultimate Weapon to Streamline Conformity Assessment and Advance Innovation

Regulation of Medical Device Clinical Trials and Innovation in Clinical Evidence Generation

Regulatory Approach for Gene Therapies: Incorporating Human Somatic Genome Editing

Reimagining Clinical Research: The Transformation of Trial Design & Conduct 

REMS Logic Model in REMS Design, Implementation, and Evaluation

Request for Reconsideration – Overview and Experience from Bioequivalence Perspectives

Request For Reconsideration: Process Overview and Best Practices for FDA Evaluation

Safety Considerations in Clinical Drug Development

Safety Considerations in Clinical Drug Development

Selective Safety Data Collection in Clinical Trials (REdI 2024 – Drugs Track)

Session 1: Panel Discussion (FDA Generic Drug Science Workshop 2025)

Session 1: Presentations (FDA Generic Drug Science Workshop 2025)

Session 2: Panel Discussion (FDA Generic Drug Science Workshop 2025)

Session 2: Presentations (FDA Generic Drug Science Workshop 2025)

1 … 5 6 7 8 9
Share: